Background: Treatment paradigms in autoimmune hepatitis (AIH) have remained largely unchanged for decades. Studies report ≤20% of patients have sub-optimal treatment response with most requiring long-term therapy.
| INTRODUCTION
Autoimmune hepatitis (AIH) is a progressive inflammatory condition of the liver that may present in either acute or chronic forms. 1-3 If not effectively treated it can progress rapidly to acute liver failure or the development of cirrhosis. With a prevalence of approximately 17 per hundred thousand in Northern European populations the disease affects both adults and children. 4, 5 Treatment paradigms established in the 1970s and 1980s utilising corticosteroids and azathioprine to achieve and sustain remission have remained largely unchanged over several decades. 1 Although case series of patients treated in specialist centres suggest that disease remission (even using the current definition of normalised transaminase and immunoglobulin G [IgG] levels) can be achieved in up to 80% of patients, 6 there is concern that real world disease outcomes in patients treated across the spectrum of health care settings may be substantially worse. 7 This leaves patients at risk of progression to end-stage disease for which liver transplantation is the only effective therapy. [8] [9] [10] International treatment guidelines have defined initial management and ongoing treatment models in AIH. [8] [9] [10] All recommend corticosteroids in the form of prednis(ol)one or budesonide with azathioprine. The goals of treatment for patients are biochemical and histological remission, with effective control of symptoms, followed by long-term maintenance of the remission state. Ideally, this should be achieved with minimisation of the dose of corticosteroid with full withdrawal being the goal. Maintenance with azathioprine monotherapy where possible is advised in UK and European Guidelines to minimise corticosteroid side effects and their impact on quality of life. The majority of patients require long-term therapy to prevent relapse 7, 11 and increasing numbers of patients suffer with unpleasant side-effects, poorly controlled disease and a life-long immunosuppression burden. [12] [13] [14] [15] The evidence base for management of patients who are nonresponders to conventional immunosuppression is limited. Alternative immunotherapy, whilst recommended as second-and third-line treatment in patients intolerant of azathioprine, can be variable in efficacy and tolerability. [16] [17] [18] [19] [20] In AIH, the majority of data relating to treatment outcomes is derived from large referral centres. 12, 21 Even amongst these expert centres, significant differences exist in relation to approach to treatment. 22 In recent years, there has been a growing awareness of inadequacies in service provision for many common liver diseases and attention focused on the public health issues pertaining to the burden of liver disease in the UK. [23] [24] [25] To date, however, little attention has been given to rarer liver diseases such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and AIH in these documents and the unmet needs and requirements of these patient groups, whilst known, have never been properly quantified. 26, 27 Since the majority of data defining outcome and treatment of AIH are derived from tertiary centres which may not accurately reflect the full spectrum of care delivery we set out to derive a national cohort of patients representing multiple hospital practice settings in the UK. The intention of the United Kingdom Autoimmune Hepatitis (UK-AIH) consortium is to use this platform to define current "real world" practice in the management of AIH within the UK, and to develop, evaluate and implement improved approaches to treatment. The goals of this study are to evaluate current treatment practice and remission rates and determine the real-life unmet clinical needs of patients with AIH.
| METHODS
The UK-AIH platform is a UK-wide cross-sectional cohort developed to evaluate the management and outcome of adult patients with AIH in the UK and to facilitate the development, evaluation and implementation of improved therapy. A key aim is to determine the unmet needs of patients with AIH. The UK-AIH patient cohort is comprised of patients 16 years of age or older who carry a clinical diagnosis of AIH. Patients were enrolled from secondary and tertiary hospital settings from March 2014 to March 2017. The cohort described here was of prevalent patients (ie, diagnosis of AIH was typically several years before enrolment into the cohort).
Patient enrolment into this study was based on what individual
clinicians considered an a-priori diagnosis of AIH. Since patients were prevalent and recruited based on the diagnosis made at clinical presentation (typically several years before study enrolment), no attempt was made to calculate the International Autoimmune Hepatitis Group (IAIHG) 28 Figure 1 illustrates the proportion of patients in the study according to age at diagnosis divided into five categories of 20-year age brackets. In keeping with other studies, the majority of patients were diagnosed between the age of 41 and 60 years. 6, [30] [31] [32] [33] Seven hundred and thirty-four of 742 (99%) of patients with available data were abstinent from alcohol or consumed alcohol within recommended limits in accordance with UK guidelines prior to 2014 34 (below 15 units per week for women and 22 units per week for men). Of those with available data, 69/739 (9%) were current smokers (less than the 19% of the total adult UK population who are reported to be current smokers by Cancer Research UK) and 221/739 (30%) were previous smokers.
| RESULTS

| Demographics and baseline features
Fifty-one patients had undergone liver transplantation at time of accession to the study and have been excluded from further analyses (other than for age at diagnosis and the development of cirrhosis) with the denominators reflecting this.
Biochemical data allowing assessment of remission status (defined as normal ALT and IgG at time of study entry) were available for 1114 patients. Of these, 460 (41%) were not in remission at the point of study entry. Despite treatment guidelines recommending that maintenance corticosteroids not be used, 653 of 1198 patients (55%) were taking long-term corticosteroid therapy as part of their treatment regimen.
| Immunosuppression regimens
T A B L E 1 Baseline characteristics of patients at time of study entry (n = 1249) and patient-reported presence of other autoimmune conditions (n = 1192, 596 in both types of unit) 
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| DISCUSSION
In this large, nationwide study of "real world" clinical practice in AIH we have demonstrated both significant limitations in the effectiveness of care for AIH and a high degree of variability in practice and quality between unit types. Our first key observation is that the remission rate using standard criteria is only 59%; a figure falling far short of the benchmark figure of 80% demonstrated to be achievable in specialist centres with a specific interest in disease management and structures in place to deliver optimised care. 6 Second, over 50% of patients with AIH in the UK are receiving ongoing corticosteroid therapy, in spite of multiple clinical practice guidelines suggesting that maintenance should be with thiopurine monotherapy. [8] [9] [10] Third, there was apparent confusion and inconsistency around appropriate treatment with 29 individual treatment regimens described even before allowing for dose variations. Finally, patients receiving care in transplant centres in the UK were more likely to achieve and maintain remission than those looked after in other care locations, despite an apparent bias towards a more severe disease phenotype.
The demographic characteristics and disease associations of the study population were in keeping with previous published series although concurrent PSC was more common in transplant units. 4, 32, 35 This suggests that differences in the behaviour of the cohort long term are unlikely to be attributable to the characteristics of the population, but rather, the care received. Risk variation was seen within the cohort with patients presenting at 20 years or younger having the highest rate of cirrhosis at diagnosis and progression to cirrhosis during follow-up. 36, 37 Disease phenotype profile in this group is in keeping with previously published reports of children with AIH, particularly, Type 2 AIH associated with detectable anti-Liver Kidney Microsomal (LKM) antibodies in serum. 38 The rate of corticosteroid use was high in our cohort with 55% of patients remaining on either prednisolone or budesonide. Recently published data from the UK-AIH study show that the use of corticosteroids is strongly associated with decreased health-related quality of life that is independent of biochemical remission status. 39 However, we know from published data that an azathioprine dose of up to 2 mg/kg/d can result in enhanced long-term remission rates in AIH with a concomitant ability to withdraw corticosteroids entirely from the treatment regimen for the majority of patients. 40 The approach to management of AIH was different between transplant and nontransplant centres. While the overall number of treatment regimens used in transplant compared to nontransplant units was similar (26 vs 27), there was a greater likelihood of patients being exposed to an expanded range of novel treatment options in AIH management (eg, CNIs, three drug regimens or biological agents). This more nuanced and individualised approach to care in the transplant centres appears to translate to less fluctuation in the disease, with more patients in biochemical remission, and consequently is likely to be protective in relation to hepatic outcomes. 6 This "real world" study of patients with AIH demonstrates and quantifies the therapeutic challenges that have been discussed in the literature. 22, 41, 42 The poor remission rates that we report suggest that there are significant unmet needs therapeutically for patients with AIH. For the majority of other autoimmune disorders, significant strides have taken place to facilitate corticosteroid-free 43, 44 These conditions are exemplars of being beneficiaries of the novel therapeutics explosion. As an orphan disease with potential hard outcomes such as cirrhosis development, death and liver transplantation, there is a pressing need for novel therapeutic approaches and targets in AIH. Some potential targets for AIH treatment have been explored but none have been realised in clinical practice as yet. 42 Patients with liver disease, especially those with rare diseases such as AIH, are disadvantaged not just through inertia from the medical community, but are secondarily disadvantaged through an unwillingness of the pharmaceutical industry to offer the use of potentially useful therapeutic agents in clinical trials. As an example, current literature suggests that antibody therapies such as anti-CD20 or anti-TNF therapy have only been utilised in <50 patients worldwide with AIH, and even then, only in the context of late disease. 45, 46 In contrast, the alternative treatment paradigm should be one of treating early disease aggressively with potential disease modifiers or stoppers, to avoid life-long therapy with corticosteroids and other drugs that have been proven outdated for the majority of other inflammatory autoimmune disorders.
Although we believe our data shed important light on the reality of care for AIH in the UK the study has important limitations. The first is that this is an observational cohort study describing outcomes in practice. This limits the scale of the data capture and will clearly miss any very high-risk patients who died from the disease early in its course and who would thus feature in an incident but not a prevalent cohort. Our approach does avoid, however, the potential for an intensive prospective study to focus attention on, and potentially lead to artificial improvement in, the quality of the care being delivered. The second is that, self-evidently, the study relates only to practice in the UK. It would of course be of great interest to repeat the approach in other health care settings to explore whether the same limitations in care are present. Anecdote and the limited data available suggest that they are. The third is that our categorisation into transplant units and nontransplant units was a robust but slightly blunt approach. We have tried to account for centres with a In conclusion, despite its limitations the UK-AIH cohort demonstrates significant discrepancies in care delivery for patients with AIH. It outlines, in particular, the contrast between real world outcomes for a rare disease cohort and the outcomes achieved in clinical trials. It also suggests that the medical community seems comfortable in accepting both suboptimal patient outcomes and largely outmoded therapeutics for the disorder. This cohort provides evidence of the need to enhance adherence to optimal treatment approaches identified in clinical practice guidelines (through education of both clinicians and patients) and a need for more potent, and patient-acceptable, therapies for this important condition. Both areas should be research priorities moving forward.
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